No side effects were observed, and daytime alertness was consistent [4]
When these mast cells infiltrate the atrium, it induces PDGF-a (platelet-derived growth factor), which causes fibrosis in the mouse heart, causing a-fib
Take home message Success on GLP-1 medication isn't just about the number on the scale
Integration of the metabolic and bioreactor levels
Makes me wonder what is the level of adherence to a GLP-1 that's necessary to achieve the desired clinical and financial effects
Last but not least, their favorable cardiovascular (CV) properties in blood pressure, endothelial function and myocardial metabolism 2,3 exemplified in the LEADER trial 4 and other studies, 5 in which a significantly lower risk of CVD events was demonstrated with liraglutide in patients with T2DM, are of major clinical importance when considering the increased risk of CV and all-cause mortality in patients with T2DM